Optimization for Regorafenib in HCC

NCT04476329 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
7
Enrollment
OTHER
Sponsor class

Stopped Enrollment rate not sufficient to meet funding entity's corporation timeline expectations, entity terminated study's fiscal support. Termination decision was purely administrative in nature and did not involve drug or patient safety issues.

Conditions

Interventions

Sponsor

SC Liver Research Consortium, LLC

Collaborators